BR0110547A - Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptose - Google Patents
Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptoseInfo
- Publication number
- BR0110547A BR0110547A BR0110547-7A BR0110547A BR0110547A BR 0110547 A BR0110547 A BR 0110547A BR 0110547 A BR0110547 A BR 0110547A BR 0110547 A BR0110547 A BR 0110547A
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- antibody
- methods
- treating
- individual
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000034615 apoptosis-related disease Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000030833 cell death Effects 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 2
- 230000006907 apoptotic process Effects 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 210000004748 cultured cell Anatomy 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 102000053594 human TNFRSF10B Human genes 0.000 abstract 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Abstract
"ANTICORPO PURIFICADO, MéTODOS PARA INDUZIR SELETIVAMENTE MORTE CELULAR EM CéLULAS ALVO E PARA TRATAR UM INDIVìDUO COM CANCER E QUE TEM UMA DOENçA INFLAMATóRIA OU DOENçA AUTOIMUNE, PROCESSOS PARA IMBIR PROLIFERAçãO DE CéLULAS ALVO, PARA TRATAR UM INDIVìDUO COM UMA DOENçA RELACIONADA A APOPTOSE, PARA PRODUZIR UM ANTICORPO HUMANO E PARA AUMENTAR NìVEIS DE NFkB EM UMA CéLULA, COMPOSIçãO, USO DE UM ANTICORPO, áCIDO NUCLEICO ISOLADO, VETOR, CéLULA CULTIVADA, POLIPEPTìDIO PURIFICADO, E, KIT COMERCIAL PARA INDUZIR APOPTOSE". Um anticorpo da invenção interage com DR5 humano para produzir efeitos agonísticos e antagonísticos a jusante do receptor incluindo inibição de proliferação celular e apoptose. Elucidou-se seq³ências de ácido nucléico e seq³ências de aminoácidos de anticorpos anti-DR5 e gerou-se vetores e células contendo e expressando estas seq³ências. Detalha-se métodos e usos para os anticorpos, incluindo tratamento de doença relacionada com apoptose e tratamento de crescimento desregulado de células.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20134400P | 2000-05-02 | 2000-05-02 | |
PCT/US2001/014151 WO2001083560A1 (en) | 2000-05-02 | 2001-05-02 | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0110547A true BR0110547A (pt) | 2004-06-22 |
Family
ID=22745456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0110547-7A BR0110547A (pt) | 2000-05-02 | 2001-05-02 | Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptose |
Country Status (28)
Country | Link |
---|---|
US (6) | US7244429B2 (pt) |
EP (4) | EP2065401B1 (pt) |
JP (4) | JP4156238B2 (pt) |
KR (2) | KR20060092292A (pt) |
CN (2) | CN101585881B (pt) |
AT (1) | ATE426615T1 (pt) |
AU (2) | AU5936601A (pt) |
BG (3) | BG65929B1 (pt) |
BR (1) | BR0110547A (pt) |
CA (1) | CA2407965C (pt) |
CY (1) | CY1109179T1 (pt) |
CZ (2) | CZ304614B6 (pt) |
DE (1) | DE60138097D1 (pt) |
DK (1) | DK1287035T3 (pt) |
EE (1) | EE05548B1 (pt) |
ES (1) | ES2323448T3 (pt) |
HK (3) | HK1050372A1 (pt) |
HU (2) | HU229417B1 (pt) |
IL (1) | IL152605A0 (pt) |
MX (1) | MXPA02010823A (pt) |
NO (2) | NO329843B1 (pt) |
NZ (1) | NZ522881A (pt) |
PL (1) | PL211733B1 (pt) |
PT (1) | PT1287035E (pt) |
RU (1) | RU2298013C2 (pt) |
TW (1) | TWI318983B (pt) |
WO (1) | WO2001083560A1 (pt) |
ZA (1) | ZA200209230B (pt) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
JP4330180B2 (ja) | 1997-03-17 | 2009-09-16 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 死ドメイン含有レセプター5 |
AU4817200A (en) * | 1999-05-04 | 2000-11-17 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
WO2003033514A1 (en) | 2001-10-19 | 2003-04-24 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
CN100475848C (zh) * | 2001-05-18 | 2009-04-08 | 麒麟麦酒株式会社 | 抗trail-r抗体 |
US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
CA2446723C (en) | 2001-05-25 | 2014-01-21 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
DE60238560D1 (de) * | 2001-11-01 | 2011-01-20 | Uab Research Foundation | Kombinationen aus anti-dr5-antikörpern und anti-dr4-antikörpern und weiteren therapeutischen agentien |
ES2357225T3 (es) * | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
WO2003054216A2 (en) * | 2001-12-20 | 2003-07-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
DE10210427A1 (de) | 2002-03-09 | 2003-10-09 | Hans Konrad Mueller-Hermelink | Humaner monoklonaler Antikörper |
CA2491669A1 (en) | 2002-07-04 | 2004-01-15 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
AU2008201431B2 (en) * | 2002-11-27 | 2011-11-24 | Irm, Llc | Methods and compositions for inducing Apoptosis in cancer cells |
KR100915257B1 (ko) * | 2002-11-27 | 2009-09-03 | 아이알엠 엘엘씨 | 단일클론 항-dr5 효능제 항체, 그 항체를 발현하는 단리된 세포, 그 항체를 포함하는 제약 조성물 및 그 항체를 사용하는 방법 |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
AU2005227322A1 (en) * | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
CN100427505C (zh) * | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体(ad5-10)及其制法与用途 |
WO2006063390A1 (en) * | 2004-12-13 | 2006-06-22 | Evogenix Ltd | Osteoprotegerin variant proteins |
JP5562521B2 (ja) | 2005-02-02 | 2014-07-30 | ザ ユーエービー リサーチ ファンデーション | アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法 |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
JP5004154B2 (ja) * | 2005-04-06 | 2012-08-22 | 一般財団法人化学及血清療法研究所 | 組換え抗ボツリヌス神経毒素抗体 |
AU2006261127B2 (en) | 2005-06-17 | 2012-03-15 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
UA97096C2 (ru) * | 2005-08-31 | 2012-01-10 | Емджен Інк. | Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2) |
PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
CN101605887B (zh) | 2006-05-16 | 2012-09-05 | 协和发酵麒麟株式会社 | 蛋白的高分泌生产方法 |
AU2007345745C1 (en) | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
KR100804126B1 (ko) | 2007-02-09 | 2008-02-19 | 아주대학교산학협력단 | 종양 괴사 인자―관련 세포사멸―유도 리간드의 수용체에특이적으로 결합하는 1가의 인간 단일클론 항체 및 그의항원결합 단편 |
WO2008154439A1 (en) * | 2007-06-08 | 2008-12-18 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
CA2695991A1 (en) * | 2007-08-09 | 2009-02-12 | Daiichi Sankyo Company, Limited | Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
ES2537806T5 (es) | 2007-10-31 | 2018-10-09 | Daiichi Sankyo Company, Limited | Método para la secreción y producción de alto nivel de proteína |
WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 dr5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
WO2011049350A2 (ko) * | 2009-10-19 | 2011-04-28 | 한올바이오파마주식회사 | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 |
BR112012010698A2 (pt) | 2009-11-05 | 2016-11-29 | Uab Research Foundation | método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo |
WO2011084623A1 (en) | 2009-12-16 | 2011-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
WO2011116344A2 (en) | 2010-03-18 | 2011-09-22 | The Uab Research Foundation | Targeting cancer stem cells |
SI2636736T1 (sl) * | 2010-10-29 | 2016-09-30 | Daiichi Sankyo Company, Limited | Novo anti-dr5 protitelesce |
EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
JP2014513128A (ja) * | 2011-05-03 | 2014-05-29 | ジェネンテック, インコーポレイテッド | 血管破壊剤とその使用 |
AU2013293062A1 (en) | 2012-07-19 | 2014-07-24 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
CN116574185A (zh) * | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
CN103074425B (zh) * | 2012-12-29 | 2014-01-01 | 深圳市第三人民医院 | Cd263基因的用途 |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
CN104710533A (zh) * | 2013-12-12 | 2015-06-17 | 中国科学院深圳先进技术研究院 | sDR5-Fc融合蛋白及其用途 |
SG10202001779UA (en) | 2015-01-20 | 2020-04-29 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
EP3250601A4 (en) | 2015-01-26 | 2018-07-11 | MacroGenics, Inc. | Multivalent molecules comprising dr5-binding domains |
CN105061604B (zh) * | 2015-08-19 | 2018-03-16 | 河南大学 | sDR5‑Fc融合蛋白突变体及其应用 |
CN109195626B (zh) | 2015-10-30 | 2022-09-13 | 银河生物技术有限责任公司 | 结合死亡受体4和死亡受体5的抗体 |
CN106924735A (zh) * | 2015-12-29 | 2017-07-07 | 上海交通大学医学院附属瑞金医院 | 多巴胺1类受体激动剂在制备肿瘤治疗药物中的用途 |
WO2017139485A1 (en) | 2016-02-09 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
BR112018067522A2 (pt) | 2016-03-01 | 2019-02-05 | Univ Of Rijeka Faculty Of Medicine | anticorpos específicos para receptor de poliovírus humano (pvr) |
KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
EP3574017A1 (en) | 2017-01-27 | 2019-12-04 | Kymab Limited | Anti-opg antibodies |
KR101926834B1 (ko) | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
BR112019025328A2 (pt) | 2017-06-07 | 2020-06-23 | Genmab B.V. | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar um indivíduo tendo um câncer e para preparar uma composição farmacêutica, e, kit de partes. |
MA50195A (fr) * | 2017-09-22 | 2020-07-29 | Immunogen Inc | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
WO2019100194A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
WO2019100193A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
CN108251443A (zh) * | 2018-01-23 | 2018-07-06 | 深圳市人民医院 | 一种tnfrsf10c重组质粒、制备方法及其应用 |
CN117126279A (zh) | 2018-03-20 | 2023-11-28 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
KR20210105890A (ko) | 2018-12-17 | 2021-08-27 | 레비토프 리미티드 | 트윈 면역 세포 인게이저 |
WO2022154664A1 (en) | 2021-01-15 | 2022-07-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
ES2284199T5 (es) * | 1997-01-28 | 2011-11-14 | Human Genome Sciences, Inc. | Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l). |
US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
JP4330180B2 (ja) | 1997-03-17 | 2009-09-16 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 死ドメイン含有レセプター5 |
AU734758B2 (en) | 1997-04-01 | 2001-06-21 | Sankyo Company Limited | Anti-fas antibodies |
JP2002512515A (ja) | 1997-04-16 | 2002-04-23 | ミレニアム ファーマシューティカルズ インク. | 腫瘍壊死因子受容体関連蛋白質TANGO−63dおよびTANGO−63e |
DE69838249T3 (de) | 1997-05-15 | 2012-01-19 | Genentech, Inc. | Anti-apo-2 antikörper |
US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
WO1999003992A1 (en) * | 1997-07-15 | 1999-01-28 | Immunex Corporation | Trail receptor |
EP0934421A1 (en) | 1997-08-06 | 1999-08-11 | Laboratorio Medinfar-Produtos Farmaceuticos LDA. | DNA INTEGRATION INTO "MYCOBACTERIUM spp." GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM |
ATE233887T1 (de) * | 1997-08-13 | 2003-03-15 | Sortech Ag | Sorptionsspeicher, anordnung und verfahren zur speicherung von wärme |
WO1999009165A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
ES2286856T3 (es) | 1997-09-12 | 2007-12-01 | Biogen Idec Ma Inc. | Receptores train ricos en cisteina. |
US7105640B2 (en) * | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
US20040120947A1 (en) | 1998-01-26 | 2004-06-24 | Genentech, Inc. | DR4 antibodies and uses thereof |
ES2368823T3 (es) | 1998-01-26 | 2011-11-22 | Genentech, Inc. | Anticuerpos del receptor 4 de muerte (dr4) y usos de los mismos. |
US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
IL145676A0 (en) * | 1999-04-12 | 2002-06-30 | Genentech Inc | Tumor necrosis factor homologs and nucleic acids encoding the same |
AU4817200A (en) | 1999-05-04 | 2000-11-17 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
WO2000067793A1 (en) | 1999-05-06 | 2000-11-16 | Human Genome Sciences, Inc. | Death domain containing receptor 4 |
CA2374599A1 (en) | 1999-05-28 | 2000-12-07 | Genentech, Inc. | Dr4 antibodies and uses thereof |
ES2267547T3 (es) | 1999-06-09 | 2007-03-16 | Genentech, Inc. | Sinergia de antagonista de receptores del ligando apo-2l y de cpt-11. |
US6294546B1 (en) | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
WO2001019861A2 (en) | 1999-09-15 | 2001-03-22 | Genentech, Inc. | Apo-2 receptor antibodies |
PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US7476383B2 (en) * | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
CA2426710A1 (en) | 2000-11-08 | 2002-10-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US6965023B2 (en) * | 2000-11-17 | 2005-11-15 | The Burnham Institute | Death domain proteins |
ATE433996T1 (de) | 2001-07-03 | 2009-07-15 | Genentech Inc | Humane dr4-antikörper und deren anwendungen |
DE60238560D1 (de) | 2001-11-01 | 2011-01-20 | Uab Research Foundation | Kombinationen aus anti-dr5-antikörpern und anti-dr4-antikörpern und weiteren therapeutischen agentien |
ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
-
2001
- 2001-05-01 TW TW090110398A patent/TWI318983B/zh not_active IP Right Cessation
- 2001-05-02 JP JP2001580185A patent/JP4156238B2/ja not_active Expired - Lifetime
- 2001-05-02 DK DK01932876T patent/DK1287035T3/da active
- 2001-05-02 US US10/275,180 patent/US7244429B2/en not_active Expired - Lifetime
- 2001-05-02 EP EP08021292.1A patent/EP2065401B1/en not_active Expired - Lifetime
- 2001-05-02 PL PL366195A patent/PL211733B1/pl not_active IP Right Cessation
- 2001-05-02 KR KR1020067015043A patent/KR20060092292A/ko not_active Application Discontinuation
- 2001-05-02 HU HU0400951A patent/HU229417B1/hu not_active IP Right Cessation
- 2001-05-02 AU AU5936601A patent/AU5936601A/xx active Pending
- 2001-05-02 EP EP08021291.3A patent/EP2065400B1/en not_active Expired - Lifetime
- 2001-05-02 AU AU2001259366A patent/AU2001259366B2/en not_active Expired
- 2001-05-02 CN CN200910137028.9A patent/CN101585881B/zh not_active Expired - Lifetime
- 2001-05-02 EP EP01932876A patent/EP1287035B1/en not_active Expired - Lifetime
- 2001-05-02 KR KR1020027014707A patent/KR100817967B1/ko active IP Right Grant
- 2001-05-02 MX MXPA02010823A patent/MXPA02010823A/es active IP Right Grant
- 2001-05-02 CN CNB018120385A patent/CN100497388C/zh not_active Expired - Lifetime
- 2001-05-02 RU RU2002132255/13A patent/RU2298013C2/ru active
- 2001-05-02 EP EP10011253.1A patent/EP2368910B1/en not_active Expired - Lifetime
- 2001-05-02 CZ CZ2002-3917A patent/CZ304614B6/cs not_active IP Right Cessation
- 2001-05-02 EE EEP200200621A patent/EE05548B1/xx unknown
- 2001-05-02 CA CA2407965A patent/CA2407965C/en not_active Expired - Lifetime
- 2001-05-02 IL IL15260501A patent/IL152605A0/xx active IP Right Grant
- 2001-05-02 BR BR0110547-7A patent/BR0110547A/pt not_active Application Discontinuation
- 2001-05-02 AT AT01932876T patent/ATE426615T1/de active
- 2001-05-02 PT PT01932876T patent/PT1287035E/pt unknown
- 2001-05-02 NZ NZ522881A patent/NZ522881A/en not_active IP Right Cessation
- 2001-05-02 WO PCT/US2001/014151 patent/WO2001083560A1/en active Application Filing
- 2001-05-02 HU HU0500800A patent/HU230399B1/hu unknown
- 2001-05-02 ES ES01932876T patent/ES2323448T3/es not_active Expired - Lifetime
- 2001-05-02 CZ CZ2006-291A patent/CZ306996B6/cs not_active IP Right Cessation
- 2001-05-02 DE DE60138097T patent/DE60138097D1/de not_active Expired - Lifetime
-
2002
- 2002-11-01 NO NO20025253A patent/NO329843B1/no not_active IP Right Cessation
- 2002-11-13 ZA ZA200209230A patent/ZA200209230B/en unknown
- 2002-11-14 BG BG107275A patent/BG65929B1/bg unknown
- 2002-11-14 BG BG109275A patent/BG109275A/en unknown
-
2003
- 2003-04-09 HK HK03102507.9A patent/HK1050372A1/xx not_active IP Right Cessation
-
2005
- 2005-04-11 JP JP2005113535A patent/JP3892466B2/ja not_active Expired - Lifetime
- 2005-08-23 BG BG109275A patent/BG66153B1/bg unknown
- 2005-09-06 NO NO20054145A patent/NO338228B1/no not_active IP Right Cessation
-
2006
- 2006-11-22 JP JP2006315093A patent/JP2007091749A/ja active Pending
-
2007
- 2007-06-08 US US11/760,491 patent/US7790165B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 JP JP2008194948A patent/JP4575975B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-17 HK HK09105423.7A patent/HK1126506A1/zh not_active IP Right Cessation
- 2009-06-24 CY CY20091100656T patent/CY1109179T1/el unknown
-
2010
- 2010-06-24 US US12/822,732 patent/US8067001B2/en not_active Expired - Fee Related
-
2011
- 2011-10-10 US US13/269,811 patent/US8329180B2/en not_active Expired - Lifetime
-
2012
- 2012-03-15 HK HK12102637.1A patent/HK1162524A1/zh not_active IP Right Cessation
- 2012-09-17 US US13/621,383 patent/US8715668B2/en not_active Expired - Fee Related
-
2014
- 2014-03-12 US US14/206,797 patent/US9700618B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0110547A (pt) | Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptose | |
BR0213844A (pt) | anticorpo purificado que se liga especificamente a um receptor dr-4 do trail, anticorpo monoclonal, composição e kit para induzir seletivamente a apoptose em células alvo que expressam dr-4, para inibir a proliferação de células alvo que expressam dr-4, para tratar um paciente com cáncer, e um paciente tendo uma doença inflamatória ou auto-imune, ácido nucleico isolado, vetor, célula cultivada, e, polipeptìdeo purificado | |
Fiorenza et al. | Complex expression of murine heat shock transcription factors | |
Lazaris-Karatzas et al. | Ras mediates translation initiation factor 4E-induced malignant transformation. | |
CN101580538B (zh) | Wt1衍生的hla-dr-结合抗原肽 | |
CN101854946B (zh) | 结肠癌和胰腺癌的重组单克隆抗体和相应抗原 | |
CN100457781C (zh) | 抗癌抗体 | |
AU687897B2 (en) | Immunoreactive peptide sequence from a 43 KD human cancer antigen | |
SG165161A1 (en) | Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof | |
ES2274542T3 (es) | Anticuerpos frente al receptor del interferon alfa/beta. | |
BR0213846A (pt) | métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição | |
AU2002240719A1 (en) | Antibodies against cancer | |
MX2011002856A (es) | Anticuerpos monoclonales para tratamiento de cancer. | |
CN113874075A (zh) | 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响 | |
BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
RU2550262C1 (ru) | Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело | |
Bernhard et al. | Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ | |
KR101783907B1 (ko) | CD66c에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물 | |
Park et al. | Induction of proline-rich tyrosine kinase2 (Pyk2) through C/EBPβ is involved in PMA-induced monocyte differentiation | |
Bast et al. | Characterization of the colony-forming cell in monoclonal gammopathies | |
Schipper et al. | Polyamine metabolism and programmed cell death in prostatic cancer cells | |
Sun et al. | Antitumour activity of a chimeric antibody against the leucocyte antigen CD48 | |
Kawamoto et al. | Impaired tumor phenotypes in class II major histocompatibility complex antigen-inducible cells originated from human lung adenocarcinoma | |
Takayama et al. | Phenotypic change of an SV40‐transformed mouse macrophage line, BB‐W‐531–2, induced by different cultural methods | |
Yoshida et al. | Induction of 19S IgM secretion in a murine pre-B cell line, 70Z/3, by cell hybridization with non-secreting myeloma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO SOLICITADA PELO DEPOSITANTE ATRAVES DA PETICAO NO 870160058101 DE 07/10/2016. |